RankAlpha logo
Back to Rankings

XENE

XenonC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Xenon has materially de-risked azetukalner in epilepsy with a positive Phase 3 X-TOLE2 readout, stated an NDA timing target for Q3 2026, and bolstered liquidity through both ATM activity and the March 2026 upsized offering; that combination supports continued commercial-readiness work and broader pipeline execution [#PR-2026-03-09] [#PR-2026-03-12] [#10-K-2026-02-26].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.1.
What can break
Clinical read-through risk if later epilepsy or neuropsychiatry studies fail to match the strength of X-TOLE2.
Momentum
55
Value
41
Sentiment
59
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $58.00 · Bull $72.00 · Bear $42.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $56.86
Why
Momentum55 · Δ7d -6.9
Value41 · Δ7d +0.1
Sentiment59 · Δ7d +5.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
55
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.9
Δ21d
-10.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
59
33% active weight
Current posture
7d trendImproving
Δ7d
+5.1
Δ21d
+12.7
Why this grade

Composite grade C. Momentum 55.4 / Value 41.1 / Sentiment 58.9

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$5.06B
Beta
0.96
Shares Out
77.28M
P/E (TTM) · Derived
-15.0
P/S (TTM)
430.58
P/FCF (TTM) · Derived
-20.36
Rev YoY
-
EPS YoY
-42.3%
Gross Margin
-
Op Margin
-4543.7%
Net Debt
-$626.91M
Current Ratio
12.52
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology